Trial Purpose

The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), biliary tract cancers (BTC), or pancreatic cancer.

View full trial information on Clinicaltrials.gov

CLINICALTRIALS.GOV IDENTIFIER:

NCT03797326

When speaking to your doctor, please have the trial identifier number available.

About The Trial

All patients will receive pembrolizumab plus lenvatinib. Your study doctor will discuss this further with you.  All patients who enroll in the trial will receive medication while on the study.*

100% will receive pembrolizumab in combination with Lenvatinib

*Patients must have a confirmed diagnosis with advanced cancer in one of six solid tumors and meet all other eligibility criteria to enroll in the trial.

Trial Phase Icon

Phase 2

Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.

Trial start Icon

Dates

  • Actual study start date February 12, 2019
  • Estimated primary completion date December 20, 2024
  • Estimated study completion date December 20, 2024

Eligibility

Conditions Icon

Conditions

Advanced Solid Tumors, Biliary Tract Cancers, Colorectal Cancer, Gastric Cancer, Glioblastoma, Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon

Sex

All

Trial locations

What Can You Do Next?

If you think this trial might be a fit and are interested in participating, take the next step to see if you are eligible.

Discuss Icon

Discuss With Your Doctor

Print this page or email it to your doctor to discuss at your next visit.

CLINICALTRIALS.GOV IDENTIFIER:

NCT03797326

When speaking to your doctor, please have the trial identifier number available.

Participating in a clinical trial is an important decision.

Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.